C-Suite Snippets: Targeting Metastasis In Cancer Therapy
In case you missed it: catch up with snippets from interviews published by In Vivo this month.
You may also be interested in...
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of malignant cells throughout the body that ends up killing the majority of cancer patients.
Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.